Signalling pathways involved in the process of mesenchymal stem cells differentiating into hepatocytes

Jun-Song Ye*†, Xiao-San Su*, J.-F. Stoltz†‡, N. de Isla† and Lei Zhang*

*BRC, First Hospital of Kun Ming, Kun Ming, 650011, China, †Lorraine University and CNRS UMR 7365, Medical College, Vandoeuvre-lès-Nancy, 54500, France and ‡CHRU Nancy, Unité Therapie Cellulaire et Tissulaire, Vandoeuvre-lès-Nancy, 54500, France

Received 28 July 2014; revision accepted 1 October 2014

Abstract
End-stage liver disease can be the termination of acute or chronic liver diseases, with manifestations of liver failure; transplantation is currently an effective treatment for these. However, transplantation is severely limited due to the serious lack of donors, expense, graft rejection and requirement of long-term immunosuppression. Mesenchymal stem cells (MSCs) have attracted considerable attention as therapeutic tools as they can be obtained with relative ease and expanded in culture, along with features of self-renewal and multidirectional differentiation. Many scientific groups have sought to use MSCs differentiating into functional hepatocytes to be used in cell transplantation with liver tissue engineering to repair diseased organs. In most of the literature, hepatocyte differentiation refers to use of various additional growth factors and cytokines, such as hepatocyte growth factor (HGF), fibroblast growth factor (FGF), epidermal growth factor (EGF), oncostatin M (OSM) and more, and most are involved in signalling pathway regulation and cell–cell/cell–matrix interactions. Signalling pathways have been shown to play critical roles in embryonic development, tumourigenesis, tumour progression, apoptosis and cell-fate determination. However, mechanisms of MSCs differentiating into hepatocytes, particularly signalling pathways involved, have not as yet been completely illustrated. In this review, we have focused on progress of signalling pathways associated with mesenchymal stem cells differentiating into hepatocytes along with the stepwise differentiation procedure.

Introduction
Numbers of aetiologies are able to cause liver dysfunction resulting in chronic liver disease and acute liver failure; many people annually, worldwide, die of liver disease. The therapy of choice for end-stage liver diseases, liver metabolic diseases and (perhaps) hepatocellular carcinoma is liver transplantation. Although achievements of liver transplantation have improved enormously and despite increasing numbers for whom this surgical procedure is performed, solutions to address the growing numbers of patients eligible for transplantation and decreasing numbers of available donors. Considering the prohibitive cost of liver transplantation, major complications (1), long-term requirement for immunosuppressive drugs (2,3) and necessity of an intensive care, pursuit of alternative therapies for end-stage liver diseases are particularly important.

Over the past decade, cell-based therapies and hepatic tissue engineering have started to be considered as promising alternatives for treatment of liver diseases (4–6). Mesenchymal stem cells (MSCs) have attracted considerable attention as potential therapeutic tools as they can be obtained with relative ease and can be expanded in culture. MSCs should be efficiently proliferating and adherent fibroblastic-type cells with features of the unique expression profile of cell surface molecules and cell–cell interaction proteins. MSCs have self-renewal and multilineage differentiation shown by mesodermal (7) and ectodermal differentiation (8), to such as adipose tissue, bone, cartilage, tendon and muscle. In addition, numerous pieces of research indicate that MSCs have low inherent immunogenicity (9) and suppress immunological responses through interaction with immune cells (10,11). This is exceptionally useful in clinical applications to therapy-resistant severe acute graft-versus-host liver diseases, liver allograft rejection and liver tissue engineering. Also, consideration of their ease of harvest and various tissue sources, such as from

Correspondence: L. Zhang, Biomedical Research Center, Affiliated Calmette Hospital of Kun Ming Medical University, Yun Nan, China. Tel.: +86-871-63188200; Fax: +86-871-63103714; E-mail: zlei01@hotmail.com

© 2015 The Authors Cell Proliferation Published by John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
bone marrow (12), adipose tissue(13), umbilical cord (14), placenta (15) and menstrual blood (16), propose MSCs to be seed cell candidates for therapeutic purposes in clinical application to liver diseases and liver cell-tissue engineering.

MSCs obtained from various sources have been demonstrated to possess endodermal differentiation potential which allows them to differentiate into hepatocyte-like cells (12–14,16) in vitro under appropriate culture conditions. Most differentiation procedures include various additional growth factors and cytokines, such as hepatocyte growth factor (HGF), fibroblast growth factor (FGF), epidermal growth factor (EGF), oncostatin M (OSM) and more. HGF is a mesenchymally derived, pleiotropic, multifunctional growth factor that acts as an important regulator of diverse processes, including mitogenesis, motogenesis, morphogenesis and apoptosis, in a variety of cell types (17,18). It exerts its biological effects through the HGF receptor (19), c-Met, which is expressed by normal hepatocytes, gastric and intestinal epithelium, ovarian and endometrial endothelia. FGF, on the other hand, is a fundamental member of heparin-binding proteins and interacts with cell surface-associated heparan sulphate proteoglycans shown to be essential for FGF signal transduction (20,21). FGF is a key player in processes of proliferation and differentiation of a wide variety of cells and tissues (21,22). EGF is the founding member of the EGF-family of proteins and is a growth factor that stimulates proliferation and differentiation by binding to its receptor EGFR (21,23,24). OSM is a pleiotropic cytokine that belongs to the interleukin 6 (IL-6) group of cytokines (25) which closely resembles leukaemia inhibitory factor (LIF) in both structure and function, and has been proven to be important in liver development (26–28). These growth factors and the cytokine are involved in hepatocyte differentiation together with other differentiation regents, such as dexamethasone (29,30), insulin–transferrin–selenium (ITS) (31,32) and L-ascorbic acid (33) and are involved in enormous varieties of signalling transduction pathways.

Signal transduction and communication involve binding of extracellular signalling molecules and ligands to cell surface receptors to trigger intracellular events. Signalling pathways have been shown to play critical roles in embryonic development, tumourigenesis, tumour progression, apoptosis and cell-fate determination through pathway crosstalk-communication and cell–cell/ cell–matrix interactions (34–36). In the complex process of mesenchymal stem cells differentiating into hepatocytes, investigators define the procedure into three stages: initiation, differentiation and maturation, consistent with sequences of liver developmental processes of specification and differentiation into mature hepatocytes.

In this review, we have focused on signalling pathways associated with mesenchymal stem cells differentiating into hepatocytes in vitro, with the stepwise differentiation-tional procedure.

Passage of hepatogenesis from mesenchymal stem cells

To understand hepatocyte differentiation protocols utilizing various growth factors and cytokines related to cell development and cell communicative signalling pathways, it is essential to overview the passage of hepatogenesis from mesendoderm, in vivo.

Specification of mesendoderm to endoderm definition

This begins with establishment of the endodermal germ layer during gastrulation. Fate mapping studies in the mouse embryo at embryonic gestation day 8, indicate that embryonic liver originates from ventral foregut endoderm (37). Nodal signaling is a signal transduction pathway that is important in pattern formation and differentiation during embryo development. Nodal signalling initiates both endodermal and mesodermal formation in a concentration-dependant manner, low Nodal doses inducing mesoderm while higher doses inducing endoderm (38). Huelsken et al. (39) revealed that lacking Nodal, or β-catenin, mouse embryos fail to form appropriate primitive development, indicating that the canonical Wnt pathway and Nodal act in synergy to specify definitive endoderm. Nodal signalling stimulates expression of a critical set of endoderm transcription factors including HMG domain DNA-binding factor Sox17 and fork head domain proteins Foxa1–3 (HNF3α/β/γ) (40) which in turn regulate a cascade of genes committing cells to the endoderm lineage. Recent research has also indicted that treatment with high Activin A and Wnt3a enabled ED-cells to differentiate into endodermal lineages (41).

Specification of the hepatoblast

The hepatoblast structure begins with an invagination in the ventral domain of the foregut (42). By embryonic day (ED) 8.5, specification of the hepatoblast is defined to a portion of the ventral foregut endoderm adjacent to the heart, and with the embryo developing the endoderm, forms a gut tube. The liver domain moves to the midgut (43). Establishment of foregut progenitors is an important step in hepatogenesis as in vivo only, the foregut endoderm (but not midgut nor hindgut) is competent to develop into the liver (37,42,44). As dependent on appropriate Activin/ Nodal signalling in the definitive endoderm at early stages.
of differentiation, the hepatoblast responds to cAMP and is able to differentiate further into hepatic progenitors, using fibroblast growth factor 10, retinoic acid and an inhibitor of Activin/Nodal receptor in vitro (45). Wnt/β-catenin signalling is not only a critical effect during hepatoblast specification (42), but also plays important roles in hepatoblast cell proliferation and differentiation (46). Further investigation (47) has suggested that hepatoblasts derived from direct conversion of non-hepatic endodermal cells, can form in the endoderm posterior to the liver by activation of Wnt/β-catenin signalling. This manifests that the Wnt/β-catenin pathway exerts autonomy in endodermal cells to induce hepatic conversion. In summary, these results demonstrate that Wnt/β-catenin signalling can induce fate change of non-hepatic endodermal cells to hepatoblast fate, during specification of the hepatoblast.

**Determination of hepatocytes**

Differentiation of bi-potential hepatoblasts into hepatocytes or biliary epithelial cells (BECs) begins around ED13 of mouse development when the cell population is considered to be the foetal source of hepatic progenitor cells (48,49). Bi-potential hepatoblasts express foetal liver genes (e.g. *alpha foetal protein*, AFP) as well as markers of both hepatocytes albumin (ALB) and BEC cytokeratin 19 (CK19). Evidence suggests that TGFβ and Wnt signals restrain expression of hepatogenic transcription factors from the periportal mesenchyme (50), such as HNF4 and C/EBP, but strengthen expression of BEC promoting transcription factors, such as onecut1 (OC1), onecut2 (OC2) and hepatocyte nuclear factor1β (HNF1β) in adjacent hepatoblasts. Continued Notch signalling pathway from the periportal mesenchyme promotes ductal plate remodelling (51,52) along the cholangiocyte lineage, while cytokine oncostatin M (OSM) in combination with HGF promotes hepatocyte differentiation (27,53,54) and complements glucocorticoid hormones and HGF to trigger complete hepatic maturation (55). Interestingly, although evidence (47) supports the role of β-catenin in proliferation and differentiation of hepatoblasts during liver bud expansion, Lade et al. (56) utilized truncated 75 kDa β-catenin, which appears in developing liver; its localization and appearance in hepatocytes coincides with hepatocyte maturation. Lade et al. further demonstrate that this form of β-catenin is produced post-translationally via proteolytic cleavage of its N-terminal 95 amino acids by calpain, and that it localizes to membranes and nuclei of hepatocytes in late foetal liver. This indicates that calpain-mediated cleavage of β-catenin plays a role in inducing hepatocyte maturation in mouse and human liver.

Together, various signalling pathways and molecular cross-talk events are patterned to occur appropriately and temporally and accomplish homeostatic regulation of hepatogenesis (Table 1).

**Protocols for mesenchymal stem cells (MSCs) differentiating into hepatocytes**

MSCs obtained from various sources have been demonstrated to have endodermal potential enabling them to differentiate into hepatocyte-like cells (12–14,16) in vitro under appropriate culture conditions. It is essential to include adequate stimulus for maintenance of cell function, such as growth factors, hormones and cytokines during induction of hepatocyte differentiation in vitro. Various protocols are well established, while they may differ considerably in detail; this causes difficulty in standardization of hepatocyte acquirement. To recapitulate liver development, we address *in vitro* hepatocyte differentiation in three stages: initiation, differentiation and maturation, and focus on the signalling pathways involved in each.

**Initiation**

Mesenchymal stem cells were initially described as being from the bone marrow and termed as mesodermally-derived non-haematopoietic bone marrow cells, while hepatocytes are the principal cell type of the liver, derived from the embryonic endoderm. Though MSCs have the capacity to differentiate into mesodermal and non-mesodermal-derived tissues according to product-orientation induction medium, definition and specification of ‘endoderm’ is essential and considered to be the initiation stage in the process of hepatocyte differentiation in vitro (40,45,57). Activin/Nodal family members initiate mesendodermal/endodermal transition when Activin A expression elevates 3-fold compared to baseline. Activin/Nodal family members release inhibitory signals generated by phosphoinositide 3-kinase (PI3K) through insulin/IGF (58). Although, Toivoen et al. have shown that definitive endodermal cells derived from human pluripotent stem cells with high Activin A and Wnt3a treatment have been able to differentiate further into both hepatic and pancreatic lineages (41), Filby et al. demonstrated that stimulation of the Nodal signalling pathway with Activin A was insufficient to induce definitive endoderm formation from unrestricted somatic stem cells (59). So et al. used mosaic analysis with a transgenic cell line expressing Axin1 and showed when Axin1, a central component of the β-catenin destruction complex, was greatly overexpressed via heat shock, 17 h post-fertilization, liver size was greatly reduced in Axin1-overexpressing embryos compared to
controls. This suggested that Wnt/β-catenin signalling autonomously induced non-hepatic endodermal cells to the liver fate (47). Characteristic time-dependent expression of transcriptional factors HNF4α, C/EBPα, and C/EBPβ during hepatocyte differentiation by bone marrow stem cells demonstrates that expression of these transcription factors is closely related to initiation and maintenance of hepatocyte differentiation (50,60). Hence, in the initiation stage of hepatocyte differentiation, MSCs can be induced to become a homogenous population of endodermal cells using a combination of activin, fibroblast growth factor 2 and bone morphogenetic protein 4 together with phosphoinositide 3-kinase (PI3K) inhibition (45,58).

### Differentiation

Cells of the hepatoblast are considered to be somatic stem/progenitor cells in foetal livers as they have high proliferative potential and ability to differentiate into both hepatocytes and cholangiocytes, during middle to late embryonic stages (42,45,61). Proliferation and differentiation of hepatoblast cells are regulated by a number of soluble factors. By addition of growth factors such as FGF4, HGF and EGF cultured for 5 days *in vitro*, MSCs can be directed into proliferation of a certain cell population, of which in the order of 50% of cells co-express hepatocyte marker AFP and cholangiocyte marker of cytokeratin 19. This result suggests that that cell population corresponds to the hepatoblast population (62). Of various growth factors, HGF has particularly attracted the attention of most investigators concerned with induction of differentiation from MSCs. For example, Forte *et al.* (63) demonstrated that HGF played an essential role in development and regeneration of the liver by comparative observations of short-term exposure of MSCs to HGF, being able to induce activation of its cognate Met receptor and downstream effectors extracellular signal-regulated kinase1/2 (ERK1/2), p38, and...
MAPK and PI3K/Akt. Long-term exposure to HGF, however, resulted in cytoskeletal rearrangement, cell migration and marked inhibition of proliferation by arrest at the G1–S checkpoint. Ghaedi et al. (17) cultured adipose stem cells on HGF/collagen(Col) spots for 2 weeks and found that mRNA levels for albumin, α-foetoprotein and α1 antitrypsin were 10–20-fold higher in stem cells cultured on HGF/Col arrays compared to stem cells on Col only spots, indicating that HGF induced expression of the hepatic phenotype in mesenchymal stem cells in vitro. Neuss et al. (19) also demonstrated that HGF and c-Met are constitutively expressed by hMSC and that expression of HGF is down-regulated by transforming growth factor-β (TGF-β). Furthermore, HGF exerts a strong chemotactic stimulus to hMSC, which may be further enhanced by autocrine signalling through the HGF c-Met pathway. While Zhou et al. (64) demonstrated HGF supported a mid/late hepatic phenotype such as ALB and dipeptidyl peptidase IV expression, but failed to induce functional hepatocyte maturation. Together, the above investigations suggest that HGF stimulates rapid hepatoblast proliferation via Wnt/β-catenin signalling and the HGF c-Met pathway and is crucial for hepatogenesis in vivo and is considered to be a critical and preliminary growth factor in the process of hepatocyte differentiation in vitro.

A further family of FGFs, is also effective in mediating early hepatic differentiation, even though optimal choice of the most suitable FGF type depends on the species involved and differentiation orientation (14,16,65). Sekson et al. (66) showed FGF1- and FGF4-enriched bipotential hepatic progenitors, whereas FGF8 further promoted embryonic liver enrichment for unipotential hepatocyte progenitors. FGFs expressed by cardinal mesoderm play a role in induction of ventral foregut endoderm to initiate early liver development. Many other growth factors are associated with hepatocyte differentiation, many researchers having demonstrated that differentiation of MSCs might be triggered and induced into hepatocytes by cooperation of HGF and FGF-4 via the HGF/c-Met signalling pathway and interaction with Wnt signalling by analysis of substantially increasing expressions of ALB, CK18 and CK19, but of strongly reduced AFP (12,14,17,67,68).

Maturation

In the late stage of hepatic differentiation in vitro, many investigations have referred to OSM, insulin–transferrin–selenium (ITS), dexamethasone and nicotinamide as major factors. OSM is an interleukin-6 (IL-6) subfamily member produced by haematopoietic cells during the early stages of embryogenesis (26). Kamiya et al. (55) demonstrated that OSM play an important role in progression of hepatocyte development to liver maturation through the signalling pathway of signal transducer and activator of transcription 3 (STAT3), despite it failing to induce the differentiated hepatocyte phenotype alone. Sakai et al. (69) also indicated that OSM alone had only very weak effects on hepatocyte function, while albumin secretion was greatly enhanced when OSM was combined with nicotinamide. NADP⁺ and NADPH play important roles in maintaining energy for cell functions including DNA repair and genomic stability. Nicotinamide, serves as primary precursor of NADP⁺ and the phosphorylated-derivative NADPH synthesis, has been shown to enhance proliferation of primary hepatocytes and formation of small hepatocyte colonies (70).

By over-expression of an activated form of C/EBPβ in dexamethasone/EGF-treated cells, Al-Adsani et al. (29) have shown that expression of hepatocyte markers increased and expression of ductal markers reduced indicating that hepatocytes and ductal cells could be induced from pancreatic exocrine cells following treatment with dexamethasone; conversion was dependent on expression of C/EBPβ and via regulation of phosphoinoside 3-kinase (PI3K) signalling pathway. On the other hand, Teramoto et al. also showed suppression of IL-6 expression by dexamethasone depended on inhibition of OSM-mediated activation of PI3K signalling during the formation of vacuoles in human foetal liver cells (27). Vollmer et al. (71) indicated that treatment of hepatocytes and hepatoma cells with OSM lead to increased protein level of HIF-1alpha under normoxic and hypoxic conditions via Janus kinase (JAK)/STAT3 and mitogen-activated protein kinase (MAPKK)/ERK1/2 pathways, and demonstrated that OSM-mediated HIF-1alpha up-regulation did not result from increase in HIF-1alpha protein stability but from increased transcription of the Hypoxia inducible factor-1alpha (HIF-1alpha) gene, suggesting that OSM treatment promoted activation of HIF-1alpha, and HIF-1alpha in reverse contributed to OSM downstream signalling events, pointing to cross-talk between cytokine and hypoxia signalling in liver development and regeneration. Researches have also reported that dexamethasone is required for maintaining expression of liver-enriched transcription factors essential for stimulating liver-specific gene transcription and promotion of expression of the hepatocyte phenotype by suppressing cell division correlated with activation of several stress signalling pathways including MAPK, SAPK/JNK and c-Jun (29,72). ITS is known to be a chemically defined supplement for supportive in vitro proliferation of various mammalian cells. For hepatogenic induction, ITS has been shown to be effective in promoting proliferation and survival of primary hepatocytes (73).
mary, different cytokines and growth factors involved in different stages of hepatocyte differentiation from MSCs are primarily related to the signalling pathways, such as the Activin/Nodal pathway, PI3K/Akt pathway, HGF/c-Met pathway, ERK1/2, MAPK, JAK/STAT3, hypoxia pathway, although further precise mechanisms remain to be further illustrated (Fig. 1).

**Conclusion**

Given the ease of isolation, expansion and their multilinage differentiation potential, additionally, superiority of low inherent immunogenicity and capability of regulating immunological responses by interaction with immune cells, MSCs are considered to be an ideal source for clinical applications for a variety of diseases and regeneration with tissue engineering. Signalling pathways have been illustrated to participate in regulation of numerous life events through cell–cell/cell–matrix interactions and crosstalk-communication between diversified signals, such as embryonic development, self-renewal and differentiation, tumourigenesis, tumour progression, apoptosis and cell-fate determination. In the research field of stem cells, most important of all, signalling pathways provide a valuable structure and method for understanding cell–cell/ cell–matrix regulation, concomitantly with providing...
information of how the stem cell microenvironment couples and integrates extrinsic with intrinsic stem-cell fate determinants and maintain the capability of self-renewal. Also, comprehensive understanding of regulatory mechanisms underlying liver development and hepatocyte differentiation has influenced diagnosis of liver diseases and further progress will be critical to future advances in liver disease therapy.

MSCs derived from various sources have been demonstrated to possess endodermal differentiation potential and can differentiate into hepatocyte-like cells in vitro under appropriate culture conditions. However, current understanding of mechanisms that facilitate hepatocyte proliferation and differentiation from mesenchymal stem cells is limited, which has hampered generation of therapeutically effective cells. Thus, it is necessary to clarify the mechanisms of MSC differentiation to build and standardise production of functional hepatocytes from MSCs. Here, we have proposed a number of directions to help guide future research into liver cell therapy and tissue engineering based on MSCs. (i) Knowledge of liver development and regeneration can best provide exhaustive information of MSC differentiation into hepatocytes in vitro. It is good choice to thoroughly investigate signalling bases and molecular mechanisms of liver development over the period from foetal to adult liver. (ii) MSCs can be induced into differently functional mature cells in terms of differently stimulative conditions. Thus, dosage and combinations of induced factors need to be accurately adjusted according to the differentiated stages of hepatogenesis. (iii) Molecular mechanisms of each step of hepatocyte differentiation from MSCs is essential for cell therapy. Both positive and negative factors responsible for initiation, differentiation and maturation of hepatocyte differentiation need to be specially considered. (iv) Although we have attempted to divide the process of hepatocyte differentiation into three stages, it is actually a continuous evolving process in which many critical factors may not only take effect at some stage of hepatocyte differentiation from MSCs. (v) In addition, attention needs to be paid to the various signalling pathways involved in stages of hepatocyte differentiation and also in cross-talk and interaction between signalling pathways, throughout the whole intricate network of signals.

In summary, more scrupulous understanding of instructive signalling pathways emanating from liver development in vivo, to MSC interaction with the microenvironment, together with a deeper analysis of cell-intrinsic mechanisms governing proliferation versus differentiation-inducing signalling pathways, is necessary to better understand the mechanisms of hepatocyte differentiation with high efficiency in vitro.

Acknowledgements

This program is supported by funds from Yun Nan province (2012FB105) and funds from Yun Nan province (2013FZ291).

References

1. Murray KF, Carithers RL Jr (2005) AASLD practice guidelines: evaluation of the patient for liver transplantation. Hepatology 41, 1407–1432.
2. Fishman JA, Rubin RH (1998) Infection in organ-transplant recipients. N. Engl. J. Med. 338, 1741–1751.
3. Cross TJ, Berry PA, Burroughs AK (2008) Infection in solid-organ transplant recipients. N. Engl. J. Med. 358, 1302.
4. Alison MR, Islam S, Lim SM (2009) Cell therapy for liver disease. Curr. Opin. Mol. Ther. 11, 364–374.
5. Bonavita AG, Quaresma K, Cotta-de-Almeida V, Pinto MA, Saravia RM, Alves LA (2010) Hepatocyte xenotransplantation for treating liver disease. Xenotransplantation 17, 181–187.
6. Gramignoli R, Tahan V, Dorko K, Skvorak KJ, Hansel MC, Zhao W et al. (2013) New potential cell source for hepatocyte transplantation: discarded livers from metabolic disease liver transplants. Stem Cell Res. 11, 563–573.
7. Castro FO, Torres A, Cabezas J, Rodriguez-Alvarez L (2014) Combined use of platelet rich plasma and vitamin C positively affects differentiation in vitro to mesodermal lineage of adult adipose equine mesenchymal stem cells. Res. Vet. Sci. 96, 95–101.
8. Heo JS, Choi SM, Kim HO, Kim EH, You J, Park T et al. (2013) Neural transdifferentiation of human bone marrow mesenchymal stem cells on hydrophobic polymer-modified surface and therapeutic effects in an animal model of ischemic stroke. Neuroscience 15, 305–318.
9. Kode JA, Mukherjee S, Joglekar MV, Hardikar AA (2009) Mesenchymal stem cells: immunobiology and role in immunomodulation and tissue regeneration. Cytotherapy 11, 377–391.
10. Bessout R, Semont A, Demarquay C, Charcosset A, Benderitter M, Mathieu N (2014) Mesenchymal stem cell therapy induces glucocorticoid synthesis in colonic mucosa and suppresses radiation-activated T cells: new insights into MSC immunomodulation. Mucosal Immunol. 7, 656–669.
11. Liu D, Xu J, Liu O, Fan Z, Liu Y, Wang F et al. (2012) Mesenchymal stem cells derived from inflamed periodontal ligaments exhibit impaired immunomodulation. J. Clin. Periodontol. 39, 1174–1182.
12. Pournasr B, Mohamadnejad M, Bagheri M, Aghdam N, Shahsavan M, Malekzadeh R et al. (2011) In vitro differentiation of human bone marrow mesenchymal stem cells into hepatocyte-like cells. Arch. Iran. Med. 14, 244–249.
13. Lee JH, Lee KH, Kim MH, Kim JP, Lee SJ, Yoon J (2012) Possibility of undifferentiated human thigh adipose stem cells differentiating into functional hepatocytes. Arch. Plast. Surg. 39, 593–599.
14. Prasajak P, Lecanansaksiri W (2013) Developing a New Two-Step Protocol to Generate Functional Hepatocytes from Wharton’s Jelly-Derived Mesenchymal Stem Cells under Hypoxic Condition. Stem Cells Int. 2013, 762196.
15. Pipino C, Shangaris P, Resca E, Zia S, Deprest J, Sebire NJ et al. (2013) Placenta as a reservoir of stem cells: an underutilized resource? Br. Med. Bull. 105, 43–68.
16. Mou XZ, Lin J, Chen JY, Li YF, Wu XX, Xiang BY et al. (2013) Menstrual blood-derived mesenchymal stem cells differentiate into
functional hepatocyte-like cells. J. Zhejiang Univ. Sci. B 14, S1–S72.

17. Ghaderi M, Tuleuova N, Zern MA, Wu J, Revzin A (2011) Bottom-up signaling from HGF-containing surfaces promotes hepatic differentiation of mesenchymal stem cells. Biochem. Biophys. Res. Commun. 407, 295–300.

18. Wang PP, Wang JH, Yan ZP, Hu MY, Lau GK, Fan ST et al. (2004) Expression of hepatocyte-like phenotypes in bone marrow stromal cells after HGF induction. Biochem. Biophys. Res. Commun. 320, 712–716.

19. Neuss S, Becher E, Woltje M, Tietze L, Jahnen-Dechent W (2004) Functional expression of HGF and HGF receptor c-met in adult human mesenchymal stem cells suggests a role in cell mobilization, tissue repair, and wound healing. Stem Cells 22, 405–414.

20. Bakhshayesh M, Soleimani M, Mehdizadeh M, Katebi M (2012) Expression of hepatocyte-like phenotypes in bone marrow stromal cells after HGF induction, J. Zhejiang Univ. Sci. B, 13(9), 961–972.

21. Salehinejad P, Alitheen NB, Mandegary A, Nematollahi-Mahani SN, Jazani E (2013) Effect of EGFR and FGF on the expansion properties of human umbilical cord mesenchymal cells. In Vitro Cell. Dev. Biol. Anim. 49, 515–523.

22. Ericson J, Norlin S, Jessell TM, Edlund T (1998) Integrated FGF and BMP signaling controls the progression of progenitor cell differentiation and the emergence of pattern in the embryonic anterior pituitary. Development 125, 1005–1015.

23. Doetzlhofer A, White PM, Johnson JE, Segil N, Groves AK (2004) In vitro growth and differentiation of mammalian sensory hair cell progenitors: a requirement for EGF and periotic mesenchyme. Dev. Biol. 272, 432–447.

24. Yan XL, Fu CJ, Chen L, Qin JH, Zeng Q, Yuan HF et al. (2012) Mesenchymal stem cells from primary breast cancer tissue promote cancer proliferation and enhance mammosphere formation partially via EGF/EGFR/Akt pathway. Breast Cancer Res. Treat. 132, 153–164.

25. Fritz DK, Kerr C, Botelho F, Stampfli M, Richards CD (2009) Oncostatin M (OSM) primes IL-13- and IL-4-induced eosinophil responses in fibroblasts: regulation of the type-II IL-4 receptor chains IL-4Ralpha and IL-13Ralpha1. Exp. Cell Res. 315, 3486–3499.

26. Urbanska-Rys H, Wiersbowska A, Stepchen H, Robak T (2000) Relationship between circulating interleukin-10 (IL-10) with interleukin-6 (IL-6) type cytokines (IL-6, interleukin-11 (IL-11), oncostatin M (OSM)) and soluble interleukin-6 (IL-6) receptor (sIL-6R) in patients with multiple myeloma. Eur. Cytokine Netw. 11, 443–451.

27. Teramoto T, Matsunaga T, Toba M, Sunazuka T, Omura S, Ohmori S (2009) Role of dexamethasone and oncostatin M on the formation of vacuoles in human fetal liver cells. Biol. Pharm. Bull. 32, 209–212.

28. Liang H, Block TM, Wang M, Nefsky B, Long R, Hafner J et al. (2012) Interleukin-6 and oncostatin M are elevated in liver disease in conjunction with candidate hepatocellular carcinoma biomarker GP73. Cancer Biomark. 11, 161–171.

29. Al-Adsani A, Burke ZD, Eberhard D, Lawrence KL, Shen CN, Rustgi AK et al. (2010) Dexamethasone treatment induces the reprogramming of pancreatic acinar cells to hepatocytes and ductal cells. PLoS ONE 5, e13650.

30. Roncero C, Fabregat I, Benito M (1995) Regulation of gene expression by interleukin-6 in fetal rat hepatocyte primary cultures: role of epidermal growth factor and dexamethasone. Hepatology 22, 1769–1775.

31. Hu J, Ma X, Bao JC, Li W, Cheng D, Gao Z et al. (2011) Insulin-transferrin-selenium (ITS) improves maturation of porcine oocytes in vitro. Zygote 19, 191–197.

32. Das ZC, Gupta MK, Ulha SJ, Lee HT (2013) Supplementation of insulin-transferrin-selenium to embryo culture medium improves the in vitro development of pig embryos. Zygote 18, 1–8.

33. Cordova B, Morato R, Izquierdo D, Paramio T, Megas T (2010) Effect of the addition of insulin-transferrin-selenium and/or L-ascorbic acid to the in vitro maturation of prepubertal bovine oocytes on cytoplasmatic maturation and embryo development. Theriogenology 74, 1341–1348.

34. Patthey C, Gunghala L (2014) Signaling pathways regulating ectodermal cell fate choices. Exp. Cell Res. 321, 11–16.

35. Zhou TB, Qin YH (2013) Signaling pathways of prohibitin and its role in diseases. J. Recept. Signal Transduct. Res. 33, 28–36.

36. Nakamura T, Lipton SA (2013) Emerging role of protein-protein transsytosis in cell signaling pathways. Antioxid. Redox Signal. 18, 239–249.

37. Tremblay KD, Zaret KS (2005) Distinct populations of endoderm cells converge to generate the embryonic liver bud and ventral foregut tissues. Dev. Biol. 280, 87–99.

38. Shen MM (2007) Nodal signaling: developmental roles and regulation. Development 134, 1023–1034.

39. Huelsken J, Vogel R, Brinkmann V, Erdmann B, Birchmeier C, Birchmeier W (2000) Requirement for beta-catenin in anterior-posterior axis formation in mice. J. Cell Biol. 148, 567–578.

40. Zorn AM, Wells JM (2007) Molecular basis of vertebrate endoderm development. Int. Rev. Cytol. 259, 49–111.

41. Toivonen S, Lundin K, Balboa D, Ustinv J, Tamminen K, Palgi J et al. (2013) Activin A and Wnt-dependent specification of human definitive endoderm cells. Exp. Cell Res. 319, 2535–2544.

42. Decaens T, Godard C, de Reynies A, Rickman DS, Tronche F, Couty JP et al. (2008) Stabilization of beta-catenin affects mouse embryonic liver growth and hepatoblast fate. Hepatology 47, 247–258.

43. McClin VA, Zorn AM (2006) Molecular control of liver development. Clin. Liver Dis. 10, 1–25, v.

44. Zorn A, StemBook. The Stem Cell Research Community StemBook; (2008) StemBook. Liver development http://www.stembook.org.

45. Touboul T, Hannan NR, Corbineau S, Martinez A, Martinet C, Branchereau S et al. (2010) Generation of functional hepatocytes from human embryonic stem cells under chemically defined conditions that recapitulate liver development. Hepatology 51, 1754–1765.

46. Matsumoto K, Miki R, Nakayama M, Tatsuni N, Yokouchi Y (2013) Wnt9a secreted from the walls of hepatic sinusoids is essential for hepatic progenitor cells activation, ductular reaction proliferation and hepatic progenitor cells to a liver fate. Biol. Open 2, 36–36.

47. Zhao R, Duncan SA (2005) Embryonic development of the liver. Hepatology 41, 956–967.

48. Roelfand P, Sancho-Bru P, Pauwelyn K, Verfaillie C (2010) Differentiation of rat multipotent adult progenitor cells to functional hepatocyte-like cells by mimicking embryonic liver development. Nat. Protoc. 5, 1324–1336.

49. Cozzolino AM, Alonzi T, Santangelo L, Mancone C, Conti B, Steincler C et al. (2013) TGFbeta overrides HNF4alpha tumor suppressing activity through GSK3beta inactivation: implication for hepatocellular carcinoma gene therapy. J. Hepatol. 58, 65–72.

50. Liew PL, Wang W, Lee YC, Huang MT, Lee WJ (2012) Roles of hepatic progenitor cells activation, ductular reaction proliferation
and Notch signaling in morbid obesity. Hepatogastroenterology 59, 1921–1927.

52 Strazza, M., Fabris, L. (2013) The balance between Notch/Wnt signaling regulates progenitor commitment during liver repair: mystery solved? J. Hepatol. 58, 181–183.

53 Nakatsukasa, H., Masuyama, H., Akahori, Y., Inoue, S., Masumoto, A., Hiramasu, Y. (2008) Relation between neonatal jaundice and oncostatin M, hepaticocyte growth factor and soluble gp130 levels in umbilical cord. Acta Obstet. Gynecol. Scand. 87, 1322–1328.

54 Zhang, SH, Wen, KM, Wu, W, Li, WY, Zhao, JN (2013) Effective application of FGFs and IGFs to enrich embryonic liver cultures for hepatic progenitors. Stem Cells 31, 330–334.

55 Kamiya, A., Kinoshita, T., Miyajima, A. (2001) Oncostatin M and hepaticocyte growth factor induce hepatic maturation via distinct signaling pathways. FEBS Lett. 492, 90–94.

56 Lade, A., Ranganathan, S., Loo, J., Monga, SP (2012) Calpain induces N-terminal truncation of beta-catenin in normal marine liver development: diagnostic implications in hepatoblastomas. J. Biol. Chem. 287, 22789–22798.

57 Ramasamy, TS, Yu, JS, Selden, C., Hodgson, H., Cui, W. (2013) Application of three-dimensional culture conditions to human embryonic stem cell-derived definitive endoderm cells enhances hepaticocyte differentiation and functionality. Tissue Eng. Part A 19, 360–367.

58 McLean, AB, D’Amour, KA, Jones, KL, Krishnamoorthy, M., Kulik, MJ, Reynolds, DM et al. (2007) Activin a efficiently specifies definitive endoderm from human embryonic stem cells only when phosphatidylinositol 3-kinase signaling is suppressed. Stem Cells 25, 29–38.

59 Filby, CE, Williamson, R., van Kooy, P., Pebbey, A., Dottori, M., Elwood, NJ et al. (2011) Stimulation of Activin A/Nodal signaling is insufficient to induce definitive endoderm formation of cord blood-derived unrestricted somatic stem cells. Stem Cell Res. Ther. 2, 16.

60 Jin, Y., Qu, Q., Zhou, L., Ji, WJ, Zhao, L., He, XD (2009) Expression of hepaticocyte-enriched transcriptional factors during the differentiation of bone marrow mesenchymal stem cell-derived hepatocytes. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 31, 330–334.

61 Wei, X., Wang, CY, Liu, QP, Li, J., Li, D., Zhao FT et al. (2008) In vitro hepatic differentiation of mesenchymal stem cells from human fetal bone marrow. J. Int. Med. Res. 36, 721–727.

62 Schmelzer, E., Zhang, L., Bruce A., Wauthier E., Ludlow J., Yao HL et al. (2007) Human hepatic stem cells from fetal and postnatal donors. J. Exp. Med. 204, 1973–1987.

63 Forte, G., Minieri, M., Cossa, P., Antenucci, D., Sala M., Gnocchi V et al. (2006) Hepatocyte growth factor effects on mesenchymal stem cells: proliferation, migration, and differentiation. Stem Cells 24, 23–33.

64 Zhou, QJ, Xiang, LX, Shao, JZ, Hu, RZ, Lu, YL, Yao H et al. (2007) In vitro differentiation of hepatic progenitor cells from mouse embryonic stem cells induced by sodium butyrate. J. Cell. Biochem. 100, 29–42.

65 Tsukada, H., Takada, T., Shiomi, H., Torii, R., Tani, T. (2006) Acidic fibroblast growth factor promotes hepatic differentiation of monkey embryonic stem cells. In Vitro Cell. Dev. Biol. Anim. 42, 83–88.

66 Sekhon, SS, Tan, X., Micsenyi, A., Bowen, WC, Monga, SP (2004) Fibroblast growth factor enriches the embryonic liver cultures for hepatic progenitors. Am. J. Pathol. 164, 2229–2240.

67 Carraro, A., Fiaschi, M., Cillo, U., Michelotto, L., Magrofuoco, E., Buggio, M. et al. (2010) A combining method to enhance the in vitro differentiation of hepatic precursor cells. Tissue Eng Part C. Methods 16, 1543–1551.

68 Lin, N., Lin, J., Bo, L., Weidong, P., Chen, S., Xu, R. (2010) Differentiation of bone marrow-derived mesenchymal stem cells into hepaticocyte-like cells in an alginate scaffold. Cell Prolif. 43, 427–434.

69 Sakai, Y., Jiang, J., Kojima, N., Kinoshita, T., Miyajima, A. (2002) Enhanced in vitro maturation of fetal mouse liver cells with oncostatin M, nicotinamide, and dimethyl sulfoxide. Cell Transplant. 11, 435–441.

70 Sato, F., Mitaka, T., Mizuguchi, T., Mochizuki, Y., Hirata K. (1999) Effects of nicotinamide-related agents on the growth of primary rat hepatocytes and formation of small hepatocyte colonies. Liver 19, 481–488.

71 Vollmer, S., Kappler, V., Kaczor J., Flugel, D., Rolvering, C., Kato N. et al. (2009) Hypoxia-inducible factor 1alpha is up-regulated by oncostatin M and participates in oncostatin M signaling. Hepatology 50, 253–260.

72 Sidhu, JS, Liu, F., Omiecinski CJ (2004) Phenytoin and morbid obesity: a uniquely sensitive indicator of hepaticocyte differentiation status: requirement of dexamethasone and extracellular matrix in establishing the functional integrity of cultured primary rat hepatocytes. Exp. Cell Res. 292, 252–264.

73 Hong, SH, Gang, EJ, Jeong, JA, Ahn C., Hwang, SH, Yang IH et al. (2005) In vitro differentiation of human umbilical cord blood-derived mesenchymal stem cells into hepaticocyte-like cells. Biochem. Biophys. Res. Commun. 330, 1153–1161.